Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Q2 2024 Results Conference Call August 7, 2024 8:00 AM ET
Company Participants
Tina Ventura - Chief Investor Relations Officer
Bill Sibold - CEO, President & Director
Mardi Dier - CFO & Senior VP
Conference Call Participants
Thomas Smith - Leerink Partners
Andrea Tan - Goldman Sachs
Andy Chen - Wolfe Research
Eliana Merle - UBS
Yasmeen Rahimi - Piper Sandler
Ritu Baral - TD Cowen
David Lebowitz - Citi
Jon Wolleben - Citizens JMP
Operator
Good day, and thank you for standing by. Welcome to the Madrigal Pharmaceuticals Second Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers presentation there will be a question and answer session. As a reminder, today's conference call is being recorded.
I would now like to introduce Ms. Tina Ventura, Chief Investor Relations Officer. Please go ahead.
Tina Ventura
Thank you, Malala. Good morning, everyone, and thank you for joining us to discuss Madrigal's second quarter 2024 earnings. We issued a press release this morning and have a slide deck that accompanies this webcast, which will post on the Investor Relations section of our website right after the call.
On the call with me today is Bill Sibold, Chief Executive Officer; and Mardi Dier, Chief Financial Officer. They'll provide prepared remarks, and then we'll take your questions. Our goal is to keep today's call to about 45 minutes.
Please note on Slide 2, we will be making certain forward-looking statements today. We refer you to our SEC filings for a discussion of risks that may cause actual results to differ from the forward-looking statements.
And with that, I will now turn the call over to Bill on Slide 3.
Bill Sibold
Well, thanks, Tina. Good morning, and thanks for joining. I'll cover three topics on our call this morning. First, an update on the Rezdiffra launch, where we are off to a strong start this quarter. Our key metrics are also showing strength and are consistent with market research reflecting high physician awareness and intent to prescribe. Second, our progress wiring system, where we are 4 months into what we expect to be about a 12-month process. This is our number one priority. As with other first-in-disease launches, we are driving a change in clinical practice and physician behavior and developing processes for efficient patient and prescription flow.
Our goal is to establish a strong foundation to support peak sales. And third, our strategy to maximize the long-term value of Rezdiffra. In addition to the untapped opportunity in the U.S., we announced today that we plan to directly launch Rezdiffra in Europe following an EMA decision expected next year.